Fc region functions of IgG – clinical significance: Which listed functions are mediated by the Fc fragment of human IgG antibodies during immune effector responses and in vivo handling?

Difficulty: Easy

Correct Answer: All of these

Explanation:


Introduction / Context:
The Fc (fragment crystallizable) portion of IgG governs interactions with host receptors and complement, shaping antibody persistence, placental transfer, and downstream effector functions such as opsonization and cell-mediated cytotoxicity. Recognizing Fc-mediated roles is essential for interpreting vaccine efficacy, monoclonal antibody engineering, and serology results.


Given Data / Assumptions:

  • IgG contains Fab (antigen binding) and Fc (effector) regions.
  • Fc engages Fc receptors (e.g., FcRn, FcγR) and complement component C1q under defined geometries.
  • Transplacental transfer relies on specialized Fc receptor pathways.


Concept / Approach:
The neonatal Fc receptor (FcRn) binds IgG Fc in acidic endosomes, recycling it to extend serum half-life, thereby influencing catabolic rate. Complement activation by IgG requires Fc-mediated C1q binding when multiple IgG molecules are arrayed on antigen. Placental transfer of maternal IgG to the fetus occurs through FcRn-dependent transport, a classic Fc function ensuring neonatal passive immunity.


Step-by-Step Solution:
Match each listed function to a known Fc-dependent mechanism. Confirm all three are well-established Fc roles. Select the inclusive option “All of these.”


Verification / Alternative check:
Therapeutic antibodies with engineered Fc domains alter half-life and effector functions, illustrating clinical control via Fc design.


Why Other Options Are Wrong:
Single statements (a–c) are true individually, so “None of these” is false; the correct comprehensive choice is “All of these.”


Common Pitfalls:
Attributing antigen specificity (a Fab property) to Fc; here the question focuses on downstream and transport roles.


Final Answer:
All of these.

More Questions from Antibody

Discussion & Comments

No comments yet. Be the first to comment!
Join Discussion